Released Mar 6, 2018, after the close
10-K filed Mar 9, 2018, 68 days after period end · 0001493152-18-003164
Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.30M$5.30M derived−11.4% vs Q4 2016+1.9% vs Q3 2017
Net Income-$639.00K-$639.00K derivedN/M vs Q4 2016N/M vs Q3 2017
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$489,000N/M
Operating Cash Flowderived-$507,000N/M
Free Cash Flowderived-$673,000N/M
Margins · derived
Operating margin-9.2%−4.2 pt vs Q4 2016
Net margin-12.1%−4.4 pt vs Q4 2016
What the release said
The release
Same quarter
| Metric | Q4 2017dderived from reported figures | Q4 2016dderived from reported figures | Q4 2015dderived from reported figures | Q4 2014dderived from reported figures |
|---|---|---|---|---|
| Revenue | $5.30M | $5.98M | $6.52M | $6.75M |
| Net Income | -$639.00K | -$459.00K | -$990.00K | -$1.72M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR